Tandem Diabetes Care Inc 8-K, filed May 27, 2022
Tandem Diabetes Care Inc (TNDM)
8-K
2022-05-27
For: 2022-05-25
View Original
Added on
April 12, 2026
About this 8-K
Tandem Diabetes Care Inc filed this 8-K on May 27, 2022, reporting on events of May 25, 2022.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 25, 2022
____________________________
(Exact name of registrant as specified in its charter)
_________
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Zip Code) | ||||||||||||||
| (Address of principal executive offices) | ||||||||||||||
Registrant’s telephone number, including area code: (858 ) 366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Symbol | Name of Exchange on Which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
___________________________
Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 25, 2022, Tandem Diabetes Care, Inc. (the “Company”) held a virtual Annual Meeting of Stockholders (the “Annual Meeting”). There were 63,939,108 shares of the Company’s common stock (“Common Stock”) outstanding on March 29, 2022, the record date for the Annual Meeting. At the Annual Meeting, 57,273,934 shares of Common Stock were present virtually or represented by proxy.
The following tables set forth the final results of the voting for the matters voted upon at the Annual Meeting. These matters are described in more detail in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission (the "SEC") on April 13, 2022 (the “Proxy Statement”).
Proposal 1: The election of two Class III directors to serve either a one-year term to expire at the 2023 annual meeting of stockholders or a three-year term to expire at the 2025 annual meeting of stockholders. The stockholders elected the two Class III directors by the following votes:
| Name of Director | For | Against | Abstain | Broker Non-Votes | ||||||||||||||||||||||
| Peyton R. Howell | 52,173,681 | 598,147 | 24,915 | 4,477,191 | ||||||||||||||||||||||
| John F. Sheridan | 51,794,146 | 977,941 | 24,656 | 4,477,191 | ||||||||||||||||||||||
Proposal 2: To approve an amendment to the Company's Amended and Restated Certificate of Incorporation to provide for the annual election of directors and the phased elimination of the classified board structure. The proposal received the following votes:
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 52,752,267 | 29,545 | 14,931 | 4,477,191 | |||||||||||||||||
Proposal 3: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement. The proposal received the following votes:
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 51,930,214 | 815,070 | 51,459 | 4,477,191 | |||||||||||||||||
Proposal 4: The ratification of the appointment of Ernst & Young LLP to serve as the Company's independent registered public accountant for the year ending December 31, 2022. The proposal received the following votes:
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 55,953,312 | 1,298,596 | 22,026 | 0 | |||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc. | ||||||||
By: | /s/ Shannon M. Hansen | |||||||
| Shannon M. Hansen | ||||||||
| Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer | ||||||||
Date: May 27, 2022